Baseline characteristics and haemodynamics of all patients in prevalence study
| Aetiology/gender | n | Age (years) | RAP (mm Hg) | mPAP (mm Hg) | CI (l/m2) | PVR (dyne.cm-5) | 6MWD (m) | NYHA II/III/IV |
| IPAH all | 85 | 51.2 (16.7)* | 9.5 (5.4) | 52.0 (13.4)* | 2.0 (0.6) | 981 (462)* | 320 (117)* | 11/64/10 |
| CTEPH all | 120 | 60.3 (16.8) | 11.1 (6.3) | 46.8 (10.5) | 2.1 (0.6) | 801 (393) | 253 (117) | 9/83/28 |
| IPAH premenopausal women | 26 | 37.7 (7.9) | 9.2 (5.9) | 53.3 (12.0)* | 2.0 (0.6) | 986 (321)* | 342 (99) | 4/21/1* |
| CTEPH premenopausal women | 26 | 38.0 (11.0) | 11.9 (6.0) | 45.0 (13.8) | 2.3 (0.7) | 752 (494) | 303 (126) | 4/14/8 |
| IPAH postmenopausal women | 34 | 64.5 (9.5)* | 9.8 (5.9) | 49.2 (12.5) | 2.0 (0.5) | 952 (464) | 278 (107)* | 1/26/7 |
| CTEPH postmenopausal women | 46 | 69.4 (9.3) | 9.5 (5.4) | 48.0 (10.2) | 2.1 (0.6) | 902 (427) | 202 (107) | 0/29/17 |
| IPAH men | 25 | 47.3 (18.1)* | 9.3 (3.9) | 54.5 (15.6)* | 2.0 (0.6) | 1014 (583)* | 343 (136) | 6/17/2 |
| CTEPH men | 48 | 63.9 (14.0) | 12.3 (7.0) | 46.6 (8.7) | 2.1 (0.5) | 729 (257) | 285 (104) | 5/40/3 |
↵* p<0.05 vs corresponding CTEPH group.
BMPR2, bone morphogenetic protein receptor type 2; CTEPH, chronic thromboembolic pulmonary hypertension; IPAH, idiopathic pulmonary arterial hypertension; mPAP, mean pulmonary artery pressure; PVR, pulmonary vascular resistance.